## Socio-demographic and genetic risk factors for drug adherence and persistence: a retrospective nationwide and biobank study across 5 medication classes and 1 845 665 individuals

M. Cordioli<sup>1,#</sup>, A. Corbetta<sup>1,2,3,#</sup>, H.M. Kariis<sup>4,#</sup>, S. Jukarainen<sup>1</sup>, P. Vartiainen<sup>1</sup>, T. Kiiskinen<sup>1</sup>, M. Ferro<sup>1</sup>, FinnGen, Estonian Biobank Research Team, M. Niemi<sup>5,6,7</sup>, S. Ripatti<sup>1,8,9</sup>, K. Lehto<sup>4</sup>, L. Milani<sup>4</sup>, A. Ganna<sup>1,10,11</sup>

<sup>1</sup> Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

<sup>2</sup> CHDS - Health Data Science Center, Human Technopole, Milan, Italy

<sup>3</sup> MOX - Laboratory for Modeling and Scientific Computing, Department of Mathematics, Politecnico di Milano, Milan, Italy

<sup>4</sup> Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

<sup>5</sup> Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland

<sup>6</sup> Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland

<sup>7</sup> Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland

<sup>8</sup> Broad Institute of MIT and Harvard, Cambridge, MA, USA

<sup>9</sup> Department of Public Health, University of Helsinki, Helsinki, Finland

<sup>10</sup> Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA

<sup>11</sup> Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA

<sup>#</sup>These authors contributed equally to this work

Correspondence to Andrea Ganna (andrea.ganna@helsinki.fi)

#### 1 Abstract

- 2 Low drug adherence is a major obstacle to the benefits of pharmacotherapies and it is therefore
- 3 important to identify factors associated with discontinuing or being poorly adherent to a
- 4 prescribed treatment regimen. Using high-quality nationwide health registry data and genome-
- 5 wide genotyping, we evaluate the impact of socio-demographic and genetic risk factors on
- 6 adherence and persistence for 5 common medication classes that require long-term, regular
- 7 therapy (N = 1 814 591 individuals from Finnish nationwide registries, 217 005 with genetic data
- 8 from Finland and Estonia).
- 9 Need for social assistance and immigration status showed a notable negative effect on
- 10 persistence and adherence across the examined medications (odd ratios between 0.48 and
- 11 0.82 for persistence and between 1.1% to 4.3% decrease in adherence) while demographic and
- 12 health factors showed comparably modest or inconsistent effects. A genome-wide scan did not
- 13 identify genetic variants associated with the two phenotypes, while some pharmacogenes (i.e.
- 14 *CYP2C9* and *SLCO1B1*) were modestly associated with persistence, but not with adherence.
- 15 We observed significant genetic correlations between medication adherence and participation in
- 16 research studies. Overall, our findings suggest that socio-economically disadvantaged groups
- 17 would benefit from targeted interventions to improve the dispensing and uptake of
- 18 pharmacological treatments.

#### 19 Introduction

Drug adherence is defined as the extent to which patients follow the prescribed therapeutic regimen when taking medications <sup>1</sup>. High adherence is considered to be crucial for the effectiveness of pharmacological treatments <sup>2</sup>, and improving adherence has been considered one of the leading challenges for healthcare professionals <sup>3</sup>. A better understanding of the risk factors driving adherence is fundamental to helping clinicians improve their clinical practice and identify patients who are at risk of poor adherence at an earlier stage.

While there are multiple dimensions of adherence, some related to the healthcare system and the mode of therapy delivery <sup>4,5</sup>, studies have shown that individuals with low adherence in placebo arms of randomized controlled trials have higher mortality<sup>6</sup>. This suggests that adherence to pharmacotherapy may be a surrogate marker for overall health behavior ("healthy adherer" effect) and that risk factors for adherence might be shared across different drugs.

32

33 Accurately estimating patients drug usage and adherence is not a trivial task. Traditionally 34 questionnaires have been used, but with the increasing availability of electronic health records, 35 studies have started investigating determinants of drug adherence and persistence using pharmacy administrative databases or insurance claims data <sup>7–11</sup>. However, most studies focus 36 37 on a single medication or condition and consider adherence over a limited follow-up available 38 due to data limitations. Few studies have investigated determinants of adherence across different medications <sup>12,13</sup>, but have only considered a limited number of demographic and 39 40 socioeconomic risk factors.

41

42 Beyond socio-demographic factors, genetics might play a role in drug adherence.

Pharmacogenomic studies have identified several genetic variants relevant to drug response
 that can increase an individual's risk for adverse drug reactions <sup>14</sup> and a recent randomized trial

45 suggested that pre-emptive testing with a 12-gene pharmacogenetic panel can significantly

46 reduce the incidence of clinically relevant adverse drug reactions <sup>15</sup>. Because an adverse drug

47 reaction decreases the likelihood of a patient continuing to take a medication, genetics might

48 impact adherence via this mechanism. Nonetheless, the impact of clinically relevant

49 pharmacogenetic variants on drug adherence has not yet been studied in large biobank-based

50 studies and considering multiple medications. Moreover, identifying novel genetic variants

51 associated with adherence might help to discover new aspects of drug response. An alternative,

52 but not mutually exclusive hypothesis, is that genetics might capture underlying health and

53 behavioral aspects that are associated with adherence. In this scenario, polygenic scores (PGS)

- 54 for certain diseases or behavioral traits might help predict drug adherence.
- 55

56 Here, we conducted a comprehensive and systematic investigation of adherence and 57 persistence to drug treatments across multiple patient-related dimensions encompassing 58 demographic, socioeconomic, and genetic factors. We used high-quality nationwide electronic 59 health record data on prescription medication purchases made at pharmacies to accurately estimate two established drug-taking phenotypes <sup>16–19</sup> (**Methods**): (a) *persistence*, defined as 60 purchasing medications for at least one year versus early discontinuation of the medication (i.e. 61 62 after one purchase) and (b) adherence, measured as Medication Possession Ratio (MPR), 63 which is the "proportion (or percentage) of days supply obtained during a specified time period" 64 (Figure 1, Methods). We considered five commonly prescribed medications that are typically 65 used for long-term, continuous, regular therapy.

66

67 We first explored the role of multiple health, demographics, and socioeconomic factors in FinRegistry<sup>20</sup>, a nationwide cohort study. Next, we considered the role of genetics in a subset of 68 the Finnish population from the FinnGen study <sup>21</sup> and the Estonian Biobank <sup>22</sup>, where genome-69 70 wide genotype information is available. We focused on well-known pharmacogenes as well as 71 on genome-wide effects. We performed a genome-wide association study (GWAS) to identify 72 potential novel genetic associations with adherence and persistence and we evaluated if these 73 results can be used for risk stratification. Finally, we used genetic correlations analysis to 74 examine the overlap between persistence and adherence and other diseases or behavioral 75 traits, and whether PGSs capturing these traits can be used to predict the two drug-taking 76 phenotypes of interest



**Figure 1 | Schematic overview of the study.** We included all individuals resident in Finland and alive on 1.1.2010 (N=5 339 804) and used information from the Finnish drug purchase register to identify individual with at least one purchase for the following medication classes: blood pressure medications, statins, antiplatelets, direct oral anticoagulants and breast cancer medications. We considered only the adult population, starting the treatment after age 18, and reconstructed individual medication purchase trajectories as a proxy to define the medication usage phenotypes: persistence and adherence. Persistence was defined as continuing the treatment for at least one year versus discontinuing it after the first purchase. We defined adherence as the Medication Possession Ratio (ratio of the quantity purchased in the observation period), for patients continuing the treatment for at least one year. Adherence is a continuous trait ranging from 0 (complete lack of adherence) to 1 (ideal adherence). \*We excluded patients with adherence above 1.1, to exclude excessive stockpiling or overbuying behaviors, but still allowing for some variability. We then studied the association of these two medication-use phenotypes with health, demographic and socio-economic factors from nationwide registries (N = 1 814 591 with complete information) and with genetic information for a subset of the population from the FinnGen study (N = 185 931) and from Estonian Biobank (N = 31 074). Figure created with Biorender.com.

#### 80 Results

# Adherence and persistence for 5 medications in 1 814 591 individuals in the general population and 217 005 individuals with genetic data

83 We considered five classes of medications: statins, blood pressure (BP) medications,

84 antiplatelets, breast cancer medications, and direct oral anticoagulants (DOAC) (ATC codes

- 85 included are described in Table 1 and Methods). For breast cancer medications and DOACs,
- 86 we included individuals with, respectively, a breast cancer or atrial fibrillation, pulmonary
- 87 embolism, or venous thromboembolism diagnosis before treatment initiation (Methods). For
- 88 antiplatelets, we did not analyze persistence, as this class of medications is frequently
- 89 prescribed for temporary treatments of 6 to 12 months. Information about the date, quantity, and
- 90 type of reimbursable medications that were purchased in pharmacies were available between
- 91 1998 and 2020 and were used to calculate adherence and persistence.
- 92

93 Our initial study population included every individual who was a resident in Finland on 1/1/2010

- 94 (N=5 339 804). 2 289 455 individuals (43% of the whole population) purchased at least one of
- the 5 medications after 18 years of age, with a total of 162 231 752 purchases.
- 96 Most individuals purchased the 5 medications for at least 12 months (ranging from 89.7% for
- 97 breast cancer medications to 64.7% for anticoagulants, except for antiplatelets (44.2%),
- 98 **Supplementary Table 1**) and were eligible for the adherence analysis (N = 1 876 212). We
- 99 further excluded 141 452 individuals who had a medication possession ratio (MPR) > 1.1, to
- account for stockpiling of medications or overbuying behaviors (Methods), and 1 270
- 101 individuals with incomplete registry information for the 8 health and socioeconomic factors
- 102 considered in the main analysis (**Supplementary Table 1**). In the persistence analysis, we
- 103 considered people discontinuing the treatment after one purchase and compared them to those
- 104 continuing for at least 12 months and were eligible for the adherence analysis. Our final study
- 105 population thus included 1 814 591 individuals, for a total of 101 102 284 purchases.
- 106
- 107 BP medications were the most purchased (N of individuals = 1 316 889) and had a mean
- 108 treatment length of over 10 years (**Table 1**). Breast cancer medications were purchased by the
- 109 fewest individuals (N=55 270) and most individuals stopped after 5 years.
- 110 Persistence was above 90% for all drugs (Figure 2). Adherence was 0.94 averaging across all
- 111 medications, highest in breast cancer medications (0.97) and lowest in statins (0.89; **Table 1**).
- 112 Adherence values were similar to those reported in the literature in comparable studies or meta-

113	analyses <sup>12,23</sup> with all medication classes having at least 80% of individuals considered as "good
114	adherers" (Figure 2). Extended Figure 1 provides an overview of adherence values by
115	showing the relationship between expected and observed consumption across the 5 medication
116	classes.
117	
118	For the subset of 185 931 individuals participating in FinnGen, persistence rates and adherence
119	distributions were consistent with the general population. In the Estonian Biobank, a cohort with
120	similar drug purchase data and genetic information available and 31 074 eligible medication
121	users, we observed generally lower persistence and adherence to statins, clopidogrel, and
122	tamoxifen ( <b>Table 1</b> ).
123	
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	
143	

Medication class	ATC codes	Cohort	N individuals	Total purchases	Proportion of persistent individuals	Mean adherence (SD)	Mean treatment length (years)
Blood Pressure	C02*, C03*, C08*, C09*	FinRegistry	1 316 889	61 213 707	0.947	0.93 (0.123)	10.755
medications		FinnGen	134 615	6 399 494	0.937	0.932 (0.121)	11.172
		FinRegistry	1 061 926	33 864 971	0.952	0.892 (0.123)	9.168
Statins	C10AA*	FinnGen	116 439	3 828 359	0.956	0.901 (0.118)	9.454
		Estonian Biobank	27 339	792 839	0.866	0.648 (0.275)	8.815
Antiplatolots	B01AC04 B01AC30	FinRegistry	138 007	3 120 237	-	0.931 (0.114)	5.528
Antiplatelets		FinnGen	12 618	285 902	-	0.933 (0.112)	5.572
Clopidogrel	B01AC04	Estonian Biobank	2712	33 466	-	0.663 (0.325)	5.455
Antiopogulanta	B01AF01, B01AF02,	FinRegistry	105 113	2 003 698	0.975	0.957 (0.094)	3.127
Anticoaguiants	B01AF03, B01AF07	FinnGen	2792	45 394	0.889	0.952 (0.101)	2.984
Breast Cancer	L02BA01, L02BG04, L02BG06, L02BG03	FinRegistry	55 270	899 671	0.984	0.969 (0.067)	4.556
medications		FinnGen	9857	145 584	0.985	0.971 (0.067)	4.128
Tamoxifen	L02BA01	Estonian Biobank	1023	8814	0.58	0.829 (0.267)	3.973

Table 1 | Descriptive statistics for the 5 medication classes included in the analysis. For each medication class, we report the ATC codes used to define the medication purchases of interest and other descriptive statistics in the general Finnish population (FinRegistry), in the subset of Finnish population with genetic data (FinnGen) and in the Estonian Biobank. Number of individuals is the total number of individuals included in the analysis, meaning the number of individuals considered for both the persistence and adherence analysis. Total purchases is the total number of purchases per each medication and each cohort considered in both analyses. Mean adherence (and its standard deviation) and the mean treatment length are reported for the individuals with at least one year long treatment (individuals considered in the adherence analysis).





**Figure 2** | **Persistence and adherence to 5 medications in the general Finnish population. a.,** Proportion of persistent individuals for each medication class considered in the analysis. **b.**, Proportion of "good adherers" (individuals with adherence greater than 0.8) for each medication class. **c.**, Adherence distribution and mean adherence (dotted line) for the 5 medication classes considered in the analysis.

#### 148 Health and socio-demographic risk factors for persistence and adherence

149 We studied the effects of the following risk factors, measured at the time of first purchase, on 150 persistence and adherence: age, sex, primary vs secondary prevention, Charlson comorbidity 151 index, years spent in education, living area, mother tongue (a proxy for first-generation 152 immigration status), and receiving any social assistance benefit in the year before starting the 153 treatment. We chose these 8 factors because they broadly capture overall health and sociodemographic aspects, were previously examined in the literature <sup>4</sup>, and were available from 154 155 nationwide registers. Basic descriptive statistics for each factor and each medication are 156 reported in **Supplementary Table 3**. Some socio-demographic factors were consistently 157 associated with lower persistence and adherence across all medications in a multivariable 158 analysis (Figure 3 considers dichotomized factors while Supplementary Tables 6 and 7 report 159 similar analysis when continuous factors are treated as such). For example, not speaking 160 Finnish or Swedish and having received social assistance benefits were associated with an 161 average of 3.2% [1.9%-4.3%] and 2% [1.1%-3.1%] lower adherence across medications, 162 respectively. Starting treatment after a related disease event (secondary prevention) was also 163 consistently associated with higher odds of persistence for statins (odds ratio (OR) = 1.53, 95% confidence interval (CI) = 1.49-1.58, P =  $4.9\times10^{-198}$ ) and increased adherence to statins and 164 antiplatelets (1.7% increase, 95% CI = 1.64-1.76% P <  $2x10^{-308}$  for statins; 0.47% increase, 95% 165 CI = 0.35-0.59%, P =  $7.4\times10^{-15}$  for antiplatelets). Age and sex showed discordant effects across 166 167 different medications after adjustment for the remaining factors. Being female showed a 168 consistent negative effect on persistence for all drugs but showed heterogeneous effects on 169 adherence. Age also showed heterogeneous effects across different medications

170 (Supplementary Tables 4-7).

171

Extending beyond these baseline factors, we further assessed the effect of one or more
concurrent treatments (i.e. polytherapy). We observed a consistent positive association between
having at least one or more treatment and higher adherence and increased odds of persistence
(Supplementary Note).

176

177 Overall, the considered health and socio-demographic factors showed a higher effect on

178 persistence than on adherence as indicated by the overall higher variance explained

179 (Supplementary Table 8).

- 181 In the Estonian Biobank, when examining variables that are present in both studies, we found
- 182 consistent results in the direction of effect and statistical significance for both persistence and
- adherence to statins and age, sex, and years spent in education, but not for secondary
- 184 prevention (**Supplementary Table 9**).





**Figure 3 | Effect of 8 health, demographic and socioeconomic factors on persistence and adherence in the Finnish population. a.**, Odds of persistence given each factor presence. ORs are from a multivariable logistic regression model, error bars represent the 95% confidence interval for the estimates. **b.**, Coefficients are estimated from a multivariable linear regression model and were rescaled to represent the percentage change in adherence given each factor presence. Error bars represent the 95% confidence interval for the estimate. Descriptive statistics for each risk factor are reported in Supplementary Table 2. In this figure we binarized the continuous risk factors to make effect sizes comparable, however results for non-binarized risk factors are available in Supplementary Table 5-6.

\*sex not included for breast cancer medications as all individuals included are females

\*\*secondary prevention defined only for statins and antiplatelets (Methods)

186

### 187 Established pharmacogenes marginally associate with persistence but not adherence

- 188 We tested the effects of 5 relevant pharmacogenes on persistence and adherence, in both
- 189 FinnGen and the Estonian Biobank. We selected the following pharmacogenes based on
- 190 guidelines from the Clinical Pharmacogenetics Implementation Consortium<sup>24–27</sup>, filtering for the
- 191 drug/gene pairs which were reported with recommended prescribing actions (e.g. alternative
- 192 therapies or dosing): ABCG2 for rosuvastatin, CYP2C9 for fluvastatin, SLCO1B1 for all statins,
- 193 CYP2C19 for clopidogrel, and CYP2D6 for tamoxifen. For each gene, we defined individual
- 194 diplotypes and grouped them into phenotypes defined based on each diplotype activity score.
- 195 We then examined the effect of each phenotype on persistence and adherence. The CYP2C9







Figure 4 | Forest plot for associations between clinically relevant pharmacogene phenotypes and persistence and adherence in FinnGen and the Estonian Biobank. a. Odds of persistence given each phenotype level. ORs are estimated from a logistic regression model, separately for each gene/drug pair. b. Percentage change in adherence given each phenotype level. Coefficients are estimated from a linear regression model, separately for each gene/drug pair. For both panels, error bars represent the 95% confidence interval for the estimate. Stars represent nominal (P < 0.05) statistical significance. Estimates are not reported for phenotypes with N < 5. For each phenotype, the frequency within each drug user group is reported in parenthesis.

#### 206 Genome-wide association study of drug adherence and persistence

207 We conducted a GWAS of persistence and adherence to each medication in FinnGen, adjusting 208 for age at initiation, year of birth, sex, genotyping batch, and first 10 genetic principal 209 components (Extended Figure 2). No variant showed significant association with either phenotype at a significance level of  $P < 1x10^{-8}$  (standard genome-wide significance corrected for 210 211 multiple testing across the 5 medications). Four SNPs, however, were genome-wide significant at the standard P < 5 x  $10^{-8}$  threshold (**Supplementary Table 12**). Notably, *rs1339882991* was 212 213 positively correlated with both persistence and adherence to BP medications and was 214 previously reported to be positively associated with hypertension <sup>28</sup>. Further characterization of 215 this and the other genome-wide significant variants is provided in the **Supplementary Note**. 216 Considering the sample size observed for statins (N = 116 439), we have at least 80% power to 217 identify genome-wide significant variants with an effect of greater than 2.7% on adherence, 218 assuming a minor allele frequency of 0.3. Such an effect is in line with what is observed for the 219 strongest epidemiological risk factor for statin adherence (Figure 3). As we expect individual 220 genetic effects for common variants to be smaller than socio-environmental, our results indicate 221 that at the current sample size, the power to identify genetic associations for adherence and

222 persistence is limited.

#### 223 Polygenic overlap between persistence, adherence and other health and behavioral traits

224 We explored the genetic overlap between persistence and adherence and 33 major diseases, 225 disease risk factors, and behavioral traits (Figure 5, Supplementary Tables 13.14). Higher 226 systolic blood pressure was genetically correlated with higher persistence to BP medications (rg = 0.77. P =  $3.1 \times 10^{-23}$ ) and with higher adherence to both statins and BP medications (rg = 0.17. 227  $P = 3.4 \times 10^{-06}$  and rg = 0.4,  $P = 3.5 \times 10^{-30}$ , respectively). On the contrary, higher LDL cholesterol 228 229 was genetically correlated with lower statins adherence (rg = -0.14, P = 0.006), although when 230 considering a GWAS of LDL cholesterol adjusted by statins usage the effect was not statistically 231 significant anymore. Notably, both adherence to statins and BP medications were positively 232 genetically correlated with participating in one or more of the optional components of UK Biobank <sup>30</sup> (*rg* between 0.11 and 0.31,  $P < 8.2 \times 10^{-3}$ ), indicating some shared effect between 233 234 drug adherence and continued participation in scientific studies.

235

We wondered if existing polygenic scores (PGS) could be used to predict adherence andpersistence and how their effect compared to that of the health and socio-demographic risk

238	factors examined before. Among the 33 PGS examined (Extended Figure 3,4 and
239	Supplementary Table 15,16) the strongest effects were observed for systolic blood pressure
240	(SBP) PGS on BP medications persistence (OR = 1.64 for 1 standard deviation (SD) in PGS,
241	95% CI = 1.60-1.68, P < $2x10^{-308}$ ) and adherence (0.8% increase per 1-SD change in PGS,
242	95% CI = 0.74-0.86%, P = 2.6x10 <sup>-126</sup> ); LDL cholesterol (adjusted for statins usage) PGS on
243	statins persistence (OR = 1.24, 95% CI = 1.20-1.28, P = $6.2 \times 10^{-47}$ ) and SBP PGS on statins
244	adherence (0.28% increase, 95% CI = 0.22-0.34%, P = $2x10^{-16}$ ); coronary artery disease PGS
245	on antiplatelets adherence (0.47% increase, 95% CI = 0.29-0.67%, P = $4.3 \times 10^{-7}$ ) and PGS for
246	schizophrenia and adherence to breast cancer medications (0.22% decrease, 95% CI = $0.1$ %-
247	0.34%, P = $4.2 \times 10^{-4}$ ). No significant association was observed between any of the PGS and
248	adherence or persistence to DOAC.

249

In the Estonian Biobank, systolic blood pressure and LDL PGS were also among the strongest effects associated with increased statin adherence, and persistence, respectively (percentage increase in adherence = 0.66%, P =  $1.11 \times 10^{-3}$ ); (OR = 1.13, 95%CI=1.093- 1.167, P =  $4.65 \times 10^{-9}$ )) (Supplementary Tables 19-20).

254

255 Overall, these PGSs could explain a lower fraction of the variance in adherence than the 256 combined effect of the health and socio-demographic risk factors examined above, after 257 accounting for age and sex (**Supplementary Table 17**).

258

Finally, we wondered whether developing a PGS for adherence would hold clinically meaningful predictive power. We used the GWAS results from FinnGen to build a PGS for statin adherence and tested its association with observed adherence in the Estonian Biobank. We found the PGS to be significantly associated with observed adherence (percentage change in adherence for 1 SD change in PGS = 0.72%, P = 1 x  $10^{-5}$ ), however, the small effect size observed suggests such PGS to have low predictive value and clinical relevance.



**Figure 5 | Genetic correlates of persistence and adherence.** Genetic correlations between 33 clinically relevant traits and persistence and adherence. Medications for which genetic correlations could not be computed are not displayed. Blue represents positive correlations, red negative. The size of each tile is proportional to the statistical significance (the bigger the tile, the lower the P-value). Correlations nominally significant at P < 0.05 are marked with a dot, while correlations which were significant after FDR correction (within each medication) are additionally marked with a circle.

\*\* UKB = UK Biobank

#### 266 Sensitivity analysis on persistence definition

- 267 Our definition of persistence resulted in higher proportions of persistent individuals compared to
- what observed in literature <sup>31</sup>. Thus, as sensitivity analysis, we consider a different definition of
- 269 persistence, looking at the proportion of individuals that stop medication within one year among
- 270 those with at least one purchase of the medication. This definition includes a broader population
- 271 (i.e. does not exclude overbuying behaviors) and consider as not persistence those individuals
- that stop after two and three purchases, as opposed to only one. With this definition,
- persistence for statins was 75.6%, consistent with the literature <sup>31</sup>. When looking at the effect of
- 274 PGS on persistence, we observed directionally consistent effects, but an overall reduction in
- 275 effect sizes despite the increased number of statistically significant associations

#### 276 (Supplementary Table 18, Supplementary Figure 1).

- 277
- 278
- 279

- 280 Discussion
- 281

Drug adherence remains a major obstacle to the benefits of pharmacotherapies. Although many external factors (e.g. healthcare- and system-related factors) contribute to drug adherence <sup>4,5</sup>, focusing on the patient-specific determinants might help in identifying patients at risk of low adherence. In this study we provide a comprehensive exploration of patient-specific factors affecting drug persistence and adherence across 5 different classes of medications, using nationwide high quality registry data and, for the first time, also exploring genetic factors.

289 Overall, our results suggest that the need for social assistance and being first-generation 290 immigrants have a moderate to large effect on drug adherence and persistence which is 291 consistent across medication classes. In comparison, demographic characteristics (age and 292 sex), comorbidity burden, and genetic factors have modest or heterogeneous effects. The only 293 health factor with a robust effect was the presence of a disease related to the medication, which 294 substantially increased adherence among those using drugs for secondary prevention. In line with previous reports <sup>23</sup>, the effects of age and sex were heterogeneous across different 295 296 medications. Nevertheless, females had consistently lower odds of persistence across all 297 medications. We speculate that a higher rate of adverse drug reactions in women compared to 298 men <sup>32,33</sup>, or lower perceived risk for cardiometabolic diseases among women can explain these 299 findings.

300

301 We performed three main genetic analyses. First, we evaluated if established pharmacogenes 302 for statins, clopidogrel and tamoxifen were associated with persistence and adherence of these 303 drugs. Our results indicate that poorer statins metabolism is associated with lower odds of 304 persistence, with a notable effect for CYP2C9 and fluvastatins. Since increased systemic 305 concentration of statins is associated with higher risk of developing statin-associated muscle 306 symptoms<sup>25</sup>, these findings are in line with the hypothesis of patients discontinuing the 307 treatment as they develop muscle symptoms. However, as these results were consistent in both 308 FinnGen and the Estonia Biobank, but were not significant after multiple-testing correction, 309 larger studies should specifically test this hypothesis. Because pharmacogenomics testing is not 310 widespread in Finland, we do not believe these results are biased by genetically-informed drug 311 prescription. Overall, the lack of association between most pharmacogenes and adherence 312 suggests that widespread pharmacogenetic testing before prescribing the medications included 313 in this study is not going to substantially improve adherence in the population, while it could be

valuable to tailor the prescribing dose of statins to avoid the risk of developing statin-associatedmuscle symptoms and improve persistence.

316

317 Second, we performed a GWAS of drug adherence and persistence and used these results to 318 understand the overlap with other traits. We did not identify robust individual genetic signals but 319 the identification of four genome-wide significant variants, two of which were not previously 320 reported to be associated with traits underlying the need for medication, warrants for larger 321 genetic studies of adherence and persistence. Our power calculations indicate that even if this 322 is the largest study of this kind, power is still limited to identify genome-wide significant 323 associations of small effects. For example, at the current sample size, the variants in the 324 pharmacogenes tested, which showed marginal significance in the targeted analysis, would not 325 have been detected at a stringent genome-wide threshold. 326 A previous study using FinnGen data compared cardiometabolic-related medication user vs 327 non-user or changes in medication use and identified > 40 loci reflecting underlying cardiometabolic risk <sup>34</sup>. The differences in the magnitude of genetic signals and genetic 328 329 correlation profiles in the current study compared to our previous study indicate that drug 330 adherence and persistence have lower genetic contribution and a stronger behavioral 331 component, which does not necessarily reflect the underlying disease risk. In our study, 332 interestingly, we observed genome-wide overlaps with a proxy for study participation indicating 333 some shared effect between adherence to drug therapy and participation in scientific research, 334 similarly to what we recently observed for COVID-19 vaccination uptake <sup>35</sup>. 335 336 Third, we explored if existing PGS could predict adherence and persistence and found the 337 strongest association between systolic blood pressure PGS and adherence/persistence to BP 338 medications. This association probably reflects individuals with higher BP being more adherent

due to higher perceived risk <sup>36</sup>. Finally, while our results could be used to generate a PGS for
statin adherence, which significantly replicated in the Estonian Biobank, the variance explained
by this PGS was low.

342

A strength of this study is the use of Finnish registries covering all drug purchases since 1998 which allows an in-depth longitudinal study of drug purchasing. For example, the average treatment length for BP medications was over 10 years. Moreover, by using nationwide data, we could confirm that adherence and persistence measures in FinnGen were similar to what was observed in the general population. Importantly, this study considers both socio-economic and 348 genetic risk factors, helping to better contextualize the results and bridging the divide between

- 349 social science and human genetics, as advocated by others <sup>37</sup>. Furthermore, we derived
- 350 adherence and persistence measures from 5 different medication classes, which allowed us to
- 351 capture adherence-related factors beyond single disease- and drug-related factors. Finally, both
- 352 epidemiological and genetic results were replicated in an external study.
- 353

354 A limitation of the study is that our definitions of persistence and adherence can be biased in 355 different ways. First, our persistence definition resulted in higher proportions of persistent individuals compared to what observed in literature<sup>31</sup>. Nonetheless, we chose this definition to 356 357 better capture early discontinuation behaviors (i.e. after the first purchase). Moreover, we 358 deemed it fair to compare these individuals only to those included in the adherence analysis, so 359 as not to include overbuying behaviors. Sensitivity analyses suggest that our results are robust 360 to a different definition of persistence and that our stricter inclusion criteria resulted in larger 361 effect sizes at the expenses of decreased statistical power.

362

363 As for the adherence definition, first we cannot know if individuals are really taking medications 364 and instead rely on the expected and observed consumption. Second, we don't have 365 information on the dose prescribed by the doctor for the entire period and rely on the suggested 366 dosage of the package. For example, individuals which are suggested by the doctor to take half-367 tablet of statins/day despite package indication, will result in low adherence. Two results 368 indicate that this behavior is not common. First, we do not see enrichment in adherence values 369 that would capture a systematic indication of non-standard dose of the medication. Second, 370 since 2015 prescription information is available as text. Using regular expressions to extract this 371 information (Methods) we found that in 2019, 96% of the prescriptions were indicating 1 statin 372 tablet/day. Finally, the observed adherence is higher than what was reported from a previous Finnish study <sup>38</sup>. Considering only individuals that had taken medication for at least 12 months 373 374 and excluding long inactive periods might have contributed to higher adherence values. 375 Nonetheless, early discontinuation is captured by our persistence measure, while long breaks in 376 drug usage might reflect hospital admission, partial emigration, or other external factors. 377 Overall, we used a definition of adherence that is more robust to large external shocks and 378 better suited to capture smaller and consistent variations in drug purchases over longer time 379 periods.

381 In conclusion, our results suggest a limited role of genetic risk factors, including clinically 382 relevant pharmacogenes, in explaining persistence and adherence for 5 common medication 383 classes that require long-term, regular therapy. While larger GWASs are needed to identify 384 smaller genetic effects, the observed genetic overlap with behavioral traits, might complicate the 385 interpretation of the results. The robust associations with measures of social deprivation 386 suggest that we need better understanding of the drivers of poor adherence in these socio-387 economically disadvantaged groups. Identifying these drivers might offer points of intervention 388 in clinical practice, or help recognizing system-wide barriers for drug adherence. 389









#### 431 Methods

#### 432 **FinRegisty and FinnGen study population**.

The FinRegistry dataset <sup>20</sup> contains data from Finnish nationwide health, demographic, and 433 434 socioeconomic registries, for a total of 7 166 416 individuals. To ensure completeness of 435 information for the variables considered in the epidemiological analysis, we included only 436 individuals who were residents in Finland and alive on 1 January 2010 (5 339 804 individuals in total). The FinnGen dataset <sup>21</sup> (Supplementary Methods) additionally contains genetic data for 437 438 a subset of the Finnish population (N = 430 885 for data freeze 10). We studied the two drug 439 usage phenotypes in adults only, meaning individuals needed to be at least 18 years old at 440 treatment initiation.

#### 441 Kela drug purchase register.

442 The Social Insurance Institution of Finland (Kela) is a government agency that provides basic 443 economic security by financial support for everyone living in Finland. The Kela drug purchase 444 register contains information about any reimbursable prescription medication bought from 445 pharmacies in Finland between 1995 and 2020. We included only purchases from 1998 on to 446 ensure better homogeneity with the data from the other registries. Each data entry contains 447 information about the date of purchase, ATC code of the medication, number of purchased 448 packages, and the Nordic Article Number (VNR) associated with the package, which gives 449 information about the quantity and dosage of the medication. When the information was 450 available, we additionally excluded those purchases made using pharmacies dose distribution 451 services, which regularly provides patients with 2-week worth of medications at a time.

452

#### 453 **The Estonian Biobank study population.**

The Estonian Biobank (EstBB) (**Supplementary Methods**) is a volunteer-based biobank that has a sample size of approximately 211,000 participants, comprising over 20% of the adult population of Estonia<sup>44</sup>. The EstBB is linked with the National Health Insurance Fund's (NHIF) database which was used as the EHR source. NHIF covers over 95% of the Estonian population as a result of universal health care in Estonia and thus provides information on diagnoses, prescribed and dispensed drugs for up to 19 years (2004-2023) from primary and specialist care. Information on prescribed and dispensed drugs is collected from all pharmacies in Estonia. The NHIF database contains information on the prescribed and dispensed drug
name, date of prescription and dispensing, International Classification of Diseases (ICD-10)
diagnosis codes, Anatomical-Therapeutic-Chemical (ATC) code of the drug, number of packs
dispensed, number of tablets in each package, and concentration of active ingredient in each
tablet. The study population in the Estonian Biobank cohort consisted of individuals that initiated
their treatment between 2007-2023.

467

#### 468 Medications included.

- 469 We included medications commonly prescribed and purchased, that are typically used for a
- 470 prolonged time and do not have a significant direct effect on wellbeing. The classes of
- 471 medication we included are as follows: statins (C10AA\* all types of statins without
- 472 differentiation), blood pressure medications (C02\* antihypertensives, C03\* diuretics, C08\* -
- 473 calcium channels blockers, C09\* agents acting on the renin-angiotensin system), antiplatelets
- 474 (B01AC04 clopidogrel and B01AC30 acetylsalicylic acid in combination with dipyridamole),
- 475 breast cancer medications (L02BA01 tamoxifen, L02BG03 anastrozole, L02BG04 letrozole,
- 476 L02BG06 exemestane), direct oral anticoagulants (DOAC) (B01AF01 rivaroxaban, B01AF02 -
- 477 apixaban, B01AF03 edoxaban, B01AE07 dabigatran etexilate). For breast cancer
- 478 medications we included only females, starting the treatment after a breast cancer diagnosis.
- 479 For DOAC, only patients starting the treatment after an atrial fibrillation diagnosis were included.480
- 481 The following drug classes or drugs were considered in the Estonian Biobank: statins drug class
- 482 (ATC C10AA\*), and separately clopidogrel (ATC B01AC04), tamoxifen (L02BA01), fluvastatin
- 483 (ATC C10AA04), and rosuvastatin (ATC C10AA07). The patients were included if they were
- 484 over the age of 18 at the start of treatment initiation.

#### 485 **Persistence**.

- We define persistence <sup>18</sup> as a binary phenotype, comparing individuals taking the medication for at least 12 months (i.e. all individuals included in the adherence analysis) versus patients earlydiscontinuing the drug after one purchase. To avoid right censoring, we considered as early discontinuation only purchases made at least 2 years before the end of follow-up. End of followup date was either death date, moving abroad date or the last date for which the data are
- 491 available (01.01.2020).

492

- 493 In the Estonian Biobank, for the non-persistence phenotype, we included individuals
- discontinuing the treatment after one purchase that contained less than 3 packages and 100
- tablets. We limited the drug supply that could be bought with one purchase to exclude
- individuals who may have stocked medications due to moving abroad or due to other reasons.
- 497 We considered as early discontinuation only purchases made before 01.01.2022 (last date for
- 498 which the data are available (28.03.2023)) and at least one year before death date.

#### 499 Adherence.

- 500 For each individual, we considered all registered purchases for each class of medication and
- 501 reconstructed individual drug purchasing trajectories. We then estimated adherence using the
- 502 Medication Possession Ratio measure (MPR) <sup>19</sup>:
- 503
- 504

$$MPR = \frac{days \ of \ supply \ during \ observation \ period}{days \ in \ observation \ period}$$

- 505
- 506 where
- 507 days of supply during observation period is the total number of tablets purchased in the
   508 trajectory, normalized assuming drug-specific daily doses (e.g. statins: 1 tablet/day)
   509 days in observation period is the sum of the intervals (in days) between all purchases
- *days in observation period* is the sum of the intervals (in days) between all purchases
   considered in the trajectory
- 511

512 When reconstructing the trajectories, we excluded the last purchase and purchases for which 513 the interval to the next one was of at least 150 days without tablets available. We considered 514 this as a break in the treatment which should not be taken into account into the adherence 515 calculation. When patients were switching to different formulations (within the same medication 516 class) and the interval between purchases was shorter than the drug supply, we discarded the 517 leftover tablets of the previous formulation. We included only individuals with at least 1 year of 518 purchases. We further excluded individuals with adherence greater than 1.1, to exclude 519 overbuying behaviors. 520

521 In the Estonian Biobank, patients were included if they had purchased at least 150 tablets.

- 522 Individual purchase trajectories were constructed and adherence was estimated using the same
- 523 criteria specified above with the exception of excluding 150 day intervals without available

- 524 treatment. The Estonian medical system does not offer services where the treatment would be
- 525 provided by the hospital without it being recorded in the drug purchase database (with the
- 526 exception of inpatient care). Therefore, we considered all gaps in drug purchases as true breaks527 in treatment.

#### 528 Sex and gender.

529 Sex was used as covariate in all of the analyses and no analyses were run separately in each 530 sex. In FinRegistry, sex was defined as recorded in the population registries from the Digital and 531 Population Data Services Agency. In FinnGen, genetically determined sex was used, after 532 guality control removal for individuals with discrepancy between sex reported in the population 533 registries and genetically determined sex. In the Estonian Biobank, sex was extracted from the 534 Estonian National Identity number which is created based on the sex recorded in the Estonian 535 Birth Registry. Quality assurance was carried out where only individuals whose sex from the 536 National Identity number matched the sex in genotype data are included.

537

#### 538 Health, demographic and socioeconomic risk factors for persistence and adherence.

- 539 We assessed the effect of the following 8 epidemiological risk factors on persistence and 540 adherence:
- 541 sex (not considered for breast cancer medications)
- 542 age at treatment initiation: age when the first purchase was recorded
- secondary prevention: whether the treatment was started after a major event related to
   the medication considered. The following diagnosis (ICD-10 codes) were considered:
- 545 statins: major coronary heart disease (I20.0, I21, I22), cerebrovascular diseases 546 (I60-I69), atherosclerosis (excluding cerebral, coronary and PAD) (I70)
- 547 antiplatelets: stroke (I60-I64), transient ischemic attack (G45), myocardial 548 infarction (I21, I22)
- 549 BP medications: no specific outcome was considered, as this is a broader class
  550 of medications
- breast cancer medications: breast cancer (C50) only secondary prevention
   patients were included
- 553-DOAC: atrial fibrillation (I48), pulmonary embolism or venous thromboembolism554(I26, I80, I87.1) only secondary prevention patients were included

- Charlson comorbidity index (at treatment initiation): we considered patients comorbidity
   status at treatment initiation by computing the Charlson comorbidity index (CCI) based
   on all the diagnoses registered previous to the first purchase. This was computed using
   the R package ICCI (<u>https://github.com/dsgelab/ICCI</u>), which uses the R package
- 559 comorbidity (<u>https://cran.r-project.org/web/packages/comorbidity/index.html</u>).
- years of education (at treatment initiation): years expected to complete the recorded
  education level. When the information at treatment baseline was not available, the first
  available record was considered.
- living area (at treatment initiation): urban *vs* rural, as classified by the Finnish digital and
   population data agency (DVV).
- 565 mother tongue: Finnish or Swedish (the two official languages of Finland) *vs* any other
  566 language
- social assistance benefits: receiving (or not) any amount of social assistance benefit in
   the year before treatment initiation
- 569 The effect sizes of each factor on persistence and adherence were derived by using a
- 570 multivariate logistic/linear regression model including all the factors, adjusting for year of birth.
- 571
- 572 For persistence, the estimated effects are reported as OR from the logistic regression model,
- 573 while for adherence we reported the percentage change in adherence by rescaling the log(OR)
- 574 from the linear model by a factor of 1.1 (maximum adherence value). To provide a better
- 575 interpretation of the results, in Figure 3 we report the effect sizes for a model where continuous
- 576 variables were dichotomized according to the following thresholds: age at initiation > 60; CCI >
- 577 5; education, university degree or higher. The same effect sizes keeping the continuous
- 578 variables as such (standardized to have mean 0 and variance equal to 1) are reported in

#### 579 **Supplementary Table 5-6**.

580

Among the health, demographic and socioeconomic factors considered in FinRegistry, the following were available in the Estonian Biobank: sex, age at treatment initiation, birth year, type of prevention, and years of education. Age at treatment initiation, birth year and years of education were standardized to have mean 0 and variance equal to 1. We assessed the association between statin persistence and adherence with these factors by using multivariate logistic and linear regression models, respectively, while only considering individuals with

587 complete information for all variables (N =27 339).

#### 588 **Pharmacogenes selection and phenotypes definition.**

589 We selected the pharmacogenes to test based on the guidelines provided by the Clinical Pharmacogenetics Implementation Consortium<sup>24</sup>. The CPIC assigns levels to gene/drug pairs 590 591 based on PharmGKB<sup>39</sup> annotation levels, recommendations by external groups (e.g. FDA, 592 EMA) or by other professional societies. We selected gene/drug pairs to match all the ATC 593 codes included in our analyses, and with a CPIC level A or B, meaning that prescribing actions 594 (e.g. alternative therapies or dosing) are recommended when the pharmacogene is present. 595 The gene/drug pairs we selected are: ABCG2 for rosuvastatin, CYP2C9 for fluvastatin, 596 SLCO1B1 for all statins, CYP2C19 for clopidogrel, and CYP2D6 for tamoxifen. 597 For each gene and for each individual included in the analyses, we defined their star alleles 598 diplotypes to test starting from the imputed phased genotypes available in FinnGen and using 599 Stargazer<sup>40,41</sup>. Having genotype data available, we could define only diplotypes captured by 600 SNP and not by structural variations (gene deletions or copy number variations). We then 601 grouped individuals based on the phenotypes also provided as output by Stargazer and 602 reflecting the metabolic activity score associated to each specific diplotype 603 (poor/decreased/increased function for SLCO1B1 and ABCG2, poor/intermediate/ultrarapid 604 metabolizer for CYP2D6, CYP2C9, CYP2C19). In the Estonian Biobank star alleles were called 605 from imputed phased genotypes available using PharmCAT<sup>42</sup> and an in-house pipeline<sup>43</sup>.

606

We used a logistic/linear regression model to estimate the association of each phenotype with persistence/adherence, adjusting by sex, age at initiation (standardized) and first 10 principal genetic components (standardized). We only tested phenotypes when defined for at least 5 individuals in the adherence analysis, or for at least 5 persistent/non-persistent individuals in the persistence analysis.

612

#### 613 Genetic risk factors of persistence and adherence.

We used REGENIE <sup>44</sup> to run a GWAS of persistence and adherence to each medication (see **Supplementary Methods** for details about genotyping and imputation in FinnGen). Persistence was treated as a binary phenotype, while adherence was kept as continuous trait, but scaled so to have mean 0 and variance equal to 1. For both analyses we adjusted for sex, genotyping batch, first 10 principal genetic components, age at first purchase and year of birth. The 619 resulting summary statistics were post-processed to keep only SNPs with INFO score ≥ 0.8 and

620 MAF ≥ 1%.

621

622 Genetic correlations between persistence and adherence and 33 publicly available traits (listed 623 in **Supplementary Table 13**) were calculated using linkage disequilibrium score regression <sup>45</sup>.

624

PGSs for the same traits were derived using PRS-CS <sup>46</sup>. Their association with persistence and
adherence was assessed by running a logistic/linear regression model for each PGS
individually, adjusting for sex, age at initiation and the first 10 genetic principal components
(standardized).

629

Weights for the same traits (**Supplementary Table 13**) were applied to the Estonian Biobank individuals using PLINK<sup>47</sup>. Similarly, the association of the PGSs with statin persistence and adherence was assessed by running a logistic or linear regression model for each PGS individually, adjusting for sex, age at initiation, and the first 10 principal components. The PGS score, age at treatment initiation, and principal components were standardized.

635

We also derived a PGS for adherence to statins from the summary statistics of the GWAS in FinnGen using PRS-CS and applied it to the Estonian Biobank individuals using PLINK. We then tested the association between statin adherence PGS and the adherence observed in the Estonian Biobank using a linear regression model, adjusting for sex, age at initiation and the first 10 genetic principal components.

641

#### 642 Acknowledgements

We are grateful to Finnish individuals, whose data made this study possible. We would also liketo thank the entire FinRegistry team for making the data available for the study.

- 645 We want to acknowledge the participants and investigators of FinnGen study. The FinnGen
- 646 project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH
- 647 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen
- 648 MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl),
- 649 Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property
- 650 Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc,

- Novartis AG, and Boehringer Ingelheim International GmbH. Following biobanks are
- acknowledged for delivering biobank samples to FinnGen: Auria Biobank
- 653 (<u>www.auria.fi/biopankki</u>), THL Biobank (<u>www.thl.fi/biobank</u>), Helsinki Biobank
- 654 (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland
- 655 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-
- 656 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
- 657 <u>US/Research\_and\_development/Finnish\_Clinical\_Biobank\_Tampere</u>), Biobank of Eastern
- 658 Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-
- 659 <u>FI/Potilaalle/Biopankki</u>), Finnish Red Cross Blood Service Biobank
- 660 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank
- 661 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank
- 662 (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-
- 663 <u>cohorts-and-arctic-biobank</u>). All Finnish Biobanks are members of BBMRI.fi infrastructure
- 664 (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (<u>https://finbb.fi/</u>) is the coordinator of
- 665 BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the
- 666 Fingenious<sup>®</sup> services (<u>https://site.fingenious.fi/en/</u>) managed by FINBB.
- 667 The authors for the Estonian Biobank would like to express our gratitude to all EstBB
- 668 participants who made it possible to conduct this study. Data analysis was carried out in part in
- 669 the High-Performance Computing Centre of University of Tartu. This work was written at writing
- 670 retreats and writing days organized by the University of Tartu Institute of Genomics. The
- 671 Estonian Biobank Research Team responsible for data collection, genotyping, QC and
- 672 imputation: Andres Metspalu, Tõnu Esko, Reedik Mägi, Mari Nelis and Georgi Hudjashov.
- This study has received funding from the European Union's Horizon 2020 research and
- 674 innovation programme under grant agreement No 101016775; from the European Research
- 675 Council (ERC) under the European Union's Horizon 2020 research and innovation program
- 676 (grant number 945733); from Academy of Finland fellowship grant N. 323116; from the
- 677 European Union through the European Regional Development Fund Project No. 2014-
- 678 2020.4.01.15-0012 GENTRANSMED; the European Union's Horizon 2020 Research and
- 679 Innovation Programme under Grant agreement 847776; the Estonian Research Council grant
- 680 number PSG615.
- 681

#### 682 Data and code availability

- 683 Data dictionaries for FinRegistry are publicly available on the FinRegistry website
- 684 (www.finregistry.fi/finnish-registry-data). Access to FinRegistry data can be obtained by
- submitting a data permit application for individual-level data for the Finnish social and health
- 686 data permit authority Findata (https://asiointi.findata.fi/). The application includes information on
- the purpose of data use; the requested data, including the variables, definitions for the target
- and control groups, and external datasets to be combined with FinRegistry data; the dates of
- the data needed; and a data utilization plan. The requests are evaluated on a case-by-case
- basis. Once approved, the data are sent to a secure computing environment Kapseli and can be
- accessed within the European Economic Area (EEA) and countries with an adequacy decision
- 692 from the European Commission.
- Access to individual level data from the Estonian Biobank can be obtained through the Estonian
- Biobank, following standard data access procedures
- 695 (https://genomics.ut.ee/en/content/estonian-biobank). All research using the Estonian Biobank
- data is regulated by the Human Genes Research Act and must be approved by the Estonian
- 697 Committee of Bioethics and Human Research.
- 698 Analysis code used to produce the results is available on GitHub at:
- 699 <u>https://github.com/dsgelab/drugs-persistence-adherence</u>
- 700

### 701 Ethics declarations

- FinRegistry is a collaboration project of the Finnish Institute for Health and Welfare (THL) and
- the Data Science Genetic Epidemiology research group at the Institute for Molecular Medicine
- Finland (FIMM), University of Helsinki. The FinRegistry project has received the following
- 705 approvals for data access from the National Institute of Health and Welfare
- 706 (THL/1776/6.02.00/2019 and subsequent amendments), DVV (VRK/5722/2019-2), Finnish
- 707 Center for Pension (ETK/SUTI 22003) and Statistics Finland (TK-53-1451-19). The FinRegistry
- 708 project has received IRB approval from the National Institute of Health and Welfare (Kokous
- 709 7/2019).
- 710 Patients and control subjects in FinnGen provided informed consent for biobank research,
- 711 based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the

- Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017),
- 713 were collected based on study-specific consents and later transferred to the Finnish biobanks
- 714 after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for
- 715 Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea.
- The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS)
- statement number for the FinnGen study is Nr HUS/990/2017.
- 718
- 719 The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers:
- 720 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
- 721 THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
- THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers:
- 723 VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution
- 724 (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA
- 725 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020),
- 726 Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020,
- 727 THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020,
- 728 THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021,
- 729 THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021,
- 730 THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics Finland
- 731 (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20)
- 732 TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases
- permission/extract from the meeting minutes on 4<sup>th</sup> July 2019.
- 734
- The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze
- 736 10 include: THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67,
- 737 BB2018\_71, BB2019\_7, BB2019\_8, BB2019\_26, BB2020\_1, BB2021\_65, Finnish Red Cross
- 738 Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020,
- 739 HUS/150/2022 § 12, §13, §14, §15, §16, §17, §18, and §23, Auria Biobank AB17-5154 and
- 740 amendment #1 (August 17 2020) and amendments BB\_2021-0140, BB\_2021-0156 (August 26
- 741 2021, Feb 2 2022), BB\_2021-0169, BB\_2021-0179, BB\_2021-0161, AB20-5926 and
- 742 amendment #1 (April 23 2020) and it's modification (Sep 22 2021), Biobank Borealis of Northern
- 743 Finland\_2017\_1013, 2021\_5010, 2021\_5018, 2021\_5015, 2021\_5023, 2021\_5017, 2022\_6001,
- 744 Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020, 53§/2021, 13§/2022,
- 745 14§/2022, 15§/2022, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020

746 & 06.10.2020), §8/2021, §9/2022, §10/2022, §12/2022, §20/2022, §21/2022, §22/2022, 747 §23/2022, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001 and amendment 25<sup>th</sup> Aug 2020, Finnish Hematological Registry and Clinical Biobank decision 18<sup>th</sup> 748 749 June 2021, Arctic biobank P0844: ARC 2021 1001. 750 751 The analysis of individual-level data from the Estonian Biobank was carried out under ethical 752 approval nr 1.1-12/624 from the Estonian Committee on Bioethics and Human Research 753 (Estonian Ministry of Social Affairs), using data according to data release application nr T12 6-754 7/GI/11086 from the Estonian Biobank. 755 756

### 757 Authors contribution

758 Study design: MC, AC, SJ, MN, KL, LM and AG. Data analysis: MC, AC and HMK. Results

759 interpretation: MC, AC, HMK, SJ, PK, TK, MF, SR, MN, KL, LM, AG. Writing – original draft:

760 MC, AC and AG. All authors were involved in further drafts of the manuscript and revised it

ritically for content. All authors gave final approval of the version to be published. MC, AC and

- 762 HMK contributed equally to this work.
- 763 **Conflicts of interest:** AG is CEO and founder of Real World Genetics Oy.

#### 764 References

- 1. Osterberg, L. & Blaschke, T. Adherence to medication. *N. Engl. J. Med.* **353**, 487–497 (2005).
- 2. Simpson, R. J., Jr & Mendys, P. The effects of adherence and persistence on clinical outcomes in
- patients treated with statins: a systematic review. *J. Clin. Lipidol.* **4**, 462–471 (2010).
- 768 3. Miller, N. H., Hill, M., Kottke, T. & Ockene, I. S. The multilevel compliance challenge:
- recommendations for a call to action. A statement for healthcare professionals. *Circulation* 95, 1085–
  1090 (1997).
- Kardas, P., Lewek, P. & Matyjaszczyk, M. Determinants of patient adherence: a review of systematic
  reviews. *Front. Pharmacol.* 4, 91 (2013).
- 5. Sabaté, E. Adherence to Long-Term Therapies: Evidence for Action. (World Health Organization,
  2003).
- 6. Simpson, S. H. *et al.* A meta-analysis of the association between adherence to drug therapy and
  mortality. *BMJ* 333, 15 (2006).
- 777 7. Chan, D. C. *et al.* Patient, physician, and payment predictors of statin adherence. *Med. Care* 48,
  778 196–202 (2010).
- 779 8. Citarella, A. *et al.* Family history of cardiovascular disease and influence on statin therapy
  780 persistence. *Eur. J. Clin. Pharmacol.* **70**, 701–707 (2014).
- 9. Shin, D. W. *et al.* Antihypertensive medication adherence in cancer survivors and its affecting factors:
  results of a Korean population-based study. *Support. Care Cancer* **19**, 211–220 (2010).
- Yang, Y. *et al.* Predictors of medication nonadherence among patients with diabetes in Medicare Part
  D programs: a retrospective cohort study. *Clin. Ther.* **31**, 2178–88; discussion 2150-1 (2009).
- 11. Kariis, H. M. et al. The role of depression and antidepressant treatment in antihypertensive
- medication adherence and persistence: Utilising electronic health record data. *J. Psychiatr. Res.* 168,
  269–278 (2023).
- Rolnick, S. J., Pawloski, P. A., Hedblom, B. D., Asche, S. E. & Bruzek, R. J. Patient characteristics
  associated with medication adherence. *Clin. Med. Res.* **11**, 54–65 (2013).
- 13. Yeaw, J., Benner, J. S., Walt, J. G., Sian, S. & Smith, D. B. Comparing adherence and persistence
- across 6 chronic medication classes. J. Manag. Care Pharm. 15, 728–740 (2009).

- 792 14. Pirmohamed, M. Pharmacogenomics: current status and future perspectives. *Nat. Rev. Genet.* 24,
  793 350–362 (2023).
- 15. Swen, J. J. et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-
- 795 label, multicentre, controlled, cluster-randomised crossover implementation study. *Lancet* 401, 347–
  796 356 (2023).
- 16. Hess, L. M., Raebel, M. A., Conner, D. A. & Malone, D. C. Measurement of adherence in pharmacy
- administrative databases: a proposal for standard definitions and preferred measures. *Ann. Pharmacother.* 40, 1280–1288 (2006).
- 800 17. Vrijens, B. *et al.* A new taxonomy for describing and defining adherence to medications. *Br. J. Clin.*801 *Pharmacol.* **73**, 691–705 (2012).
- 802 18. Cramer, J. A. *et al.* Medication compliance and persistence: terminology and definitions. *Value*803 *Health* 11, 44–47 (2008).
- 19. Andrade, S. E., Kahler, K. H., Frech, F. & Chan, K. A. Methods for evaluation of medication
  adherence and persistence using automated databases. *Pharmacoepidemiol. Drug Saf.* 15, 565–74;
  discussion 575-7 (2006).
- 807 20. Viippola, E. *et al.* Data Resource Profile: Nationwide registry data for high-throughput epidemiology
  808 and machine learning (FinRegistry). *Int. J. Epidemiol.* (2023) doi:10.1093/ije/dyad091.
- 809 21. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population.
  810 *Nature* 613, 508–518 (2023).
- 22. Leitsalu, L. *et al.* Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of
  Tartu. *Int. J. Epidemiol.* 44, 1137–1147 (2015).
- 813 23. DiMatteo, M. R. Variations in patients' adherence to medical recommendations: a quantitative review
  814 of 50 years of research. *Med. Care* 42, 200–209 (2004).
- 815 24. Relling, M. V. & Klein, T. E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the
  816 Pharmacogenomics Research Network. *Clin. Pharmacol. Ther.* 89, 464–467 (2011).
- 817 25. Cooper-DeHoff, R. M. et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for
- 818 SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. *Clin.*
- 819 *Pharmacol. Ther.* **111**, 1007–1021 (2022).

- 820 26. Lee, C. R. et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19
- 821 Genotype and Clopidogrel Therapy: 2022 Update. *Clin. Pharmacol. Ther.* **112**, 959–967 (2022).
- 822 27. Goetz, M. P. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for
- 823 CYP2D6 and Tamoxifen Therapy. *Clin. Pharmacol. Ther.* **103**, 770–777 (2018).
- 824 28. Dönertaş, H. M., Fabian, D. K., Valenzuela, M. F., Partridge, L. & Thornton, J. M. Common genetic
  825 associations between age-related diseases. *Nat Aging* 1, 400–412 (2021).
- 826 29. Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait-associated genes using
  827 large-scale genetics and functional genomics. *Nucleic Acids Res.* 49, D1311–D1320 (2021).
- 30. Tyrrell, J. *et al.* Genetic predictors of participation in optional components of UK Biobank. *Nat. Commun.* 12, 886 (2021).
- 830 31. Helin-Salmivaara, A. *et al.* Long-term persistence with statin therapy: a nationwide register study in
  831 Finland. *Clin. Ther.* **30 Pt 2**, 2228–2240 (2008).
- 832 32. Zucker, I. & Prendergast, B. J. Sex differences in pharmacokinetics predict adverse drug reactions in
  833 women. *Biol. Sex Differ.* 11, 32 (2020).
- 834 33. Brabete, A. C. *et al.* A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping
  835 Review of Pharmacovigilance Databases. *Pharmaceuticals* **15**, (2022).
- 836 34. Kiiskinen, T. *et al.* Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.
  837 *Nat. Med.* 29, 209–218 (2023).
- 838 35. Hartonen, T. *et al.* Nationwide health, socio-economic and genetic predictors of COVID-19
  839 vaccination status in Finland. *Nat Hum Behav* 7, 1069–1083 (2023).
- 840 36. Shiraly, R., Khani Jeihooni, A. & Bakhshizadeh Shirazi, R. Perception of risk of hypertension related
- 841 complications and adherence to antihypertensive drugs: a primary healthcare based cross-sectional
  842 study. *BMC Prim Care* 23, 303 (2022).
- 843 37. Harden, K. P. & Koellinger, P. D. Using genetics for social science. *Nat Hum Behav* 4, 567–576
  844 (2020).
- 845 38. Aarnio, E. J. *et al.* Register-based predictors of adherence among new statin users in Finland. *J.*846 *Clin. Lipidol.* 8, 117–125 (2014).
- 847 39. Whirl-Carrillo, M. et al. An Evidence-Based Framework for Evaluating Pharmacogenomics

- 848 Knowledge for Personalized Medicine. *Clin. Pharmacol. Ther.* **110**, 563–572 (2021).
- 40. Lee, S.-B. *et al.* Stargazer: a software tool for calling star alleles from next-generation sequencing
  data using CYP2D6 as a model. *Genet. Med.* 21, 361–372 (2019).
- 41. Lee, S.-B., Wheeler, M. M., Thummel, K. E. & Nickerson, D. A. Calling Star Alleles With Stargazer in
- 852 28 Pharmacogenes With Whole Genome Sequences. Clin. Pharmacol. Ther. 106, 1328–1337
- 853 (2019).
- 42. Sangkuhl, K. *et al.* Pharmacogenomics Clinical Annotation Tool (PharmCAT). *Clin. Pharmacol. Ther.*107, 203–210 (2020).
- 43. Reisberg, S. *et al.* Translating genotype data of 44,000 biobank participants into clinical
- pharmacogenetic recommendations: challenges and solutions. *Genet. Med.* **21**, 1345–1354 (2019).
- 44. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary
- 859 traits. *Nat. Genet.* **53**, 1097–1103 (2021).
- 860 45. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.*861 47, 1236–1241 (2015).
- 46. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian
  regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).
- 47. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage
- 865 analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).